Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update ACCESSWIRE 11 May 2021, 06:05 GMT+10 Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer Announced encouraging preliminary data from a Phase 1b trial of gedatolisib plus Ibrance® and endocrine therapy for patients with ER+/HER2- metastatic breast cancer, in which gedatolisib showed a potentially differentiated safety and tolerability profile Secured additional financing to streng...
Source: newjerseytelegraph.com
